Business Wire

AGCO Agriculture Foundation Launches COVID-19 Aid Program with $100,000 Donation to the World Food Program USA

Share

The AGCO Agriculture Foundation (AAF), a private foundation committed to ending hunger through sustainable agricultural development, today announced the launch of its COVID-19 Aid Program with a $100,000 grant to the World Food Program USA (WFP USA) in support of the United Nations World Food Programme’s (WFP) COVID-19 emergency response.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200521005211/en/

Niger, Tahoua, Allakaye, Angoual Denia, 23 July 2019 (Photo: WFP/Simon Pierre Diouf)

Niger, Tahoua, Allakaye, Angoual Denia, 23 July 2019 (Photo: WFP/Simon Pierre Diouf)

The AAF COVID-19 Aid Program’s inaugural grant to WFP USA will support the WFP, the leading humanitarian agency fighting hunger worldwide, to continue to deliver food and critical supplies at full capacity. Our donation will focus on the most vulnerable populations in Africa and Latin America.

“The urgency of hunger worldwide has become even more critical with the addition of the coronavirus, and we are directing our global support to the World Food Program USA in support of WFP’s COVID-19 relief efforts. Our funding will help monitor the impact of the pandemic, pre-position food and medical supplies in vulnerable communities in Africa and Latin America, as well as lend support to newly established supply chain coordination cells on the ground,” says Lucinda Smith, Board Chairman, AGCO Agriculture Foundation.

“We are grateful to AGCO Agriculture Foundation for their generous donation and support to raise much needed funding for WFP’s COVID-19 response efforts,” said Barron Segar, World Food Program USA President and CEO. “WFP serves as the logistics and transportation backbone to the humanitarian community and AAF’s contribution is critical to ensuring WFP can get lifesaving food and supplies to millions of the most vulnerable people.”

The AAF is matching donations up to $100,000 made at this link: www.wfpusa.org/aaf-match.

“We would like to invite our stakeholders to contribute to the World Food Program USA global emergency response to support this critical need,” said Metti Richenhagen, Managing Director, AGCO Agriculture Foundation.

“The AGCO Agriculture Foundation has launched the COVID-19 Aid Program with total funding of $500,000 and is also making grants to local non-profit organizations focused on the prevention and relief of hunger in the communities where we live and work across the globe.”

About the AGCO Agriculture Foundation (AAF)

The AGCO Agriculture Foundation (AAF), initiated by AGCO Corporation (NYSE: AGCO) in 2018, is a private foundation with the vision to prevent and relieve hunger. The foundation initiates impactful programs that support food security, foster sustainable agricultural development and build needed agricultural infrastructure in marginalized farming communities. AAF is domiciled in Vaduz, Liechtenstein and operations are managed from Duluth, Georgia, USA. For more information, please visit https://www.agcocorp.com/commitment/sustainability/focus-areas/communities.html.

About World Food Program USA

World Food Program USA is the recognized leader in America’s pursuit to end global hunger, inspiring citizens to do everything in their power to create a zero-hunger world.WFP USA works with U.S. policymakers, corporations, foundations and individuals to generate financial and in-kind resources for the United Nations World Food Programme to feed families in need around the world and to develop policies necessary to alleviate global hunger. To learn more about WFP USA’s mission, please visit us at www.wfpusa.org.

Contact information

Metti Richenhagen
Managing Director, AGCO Agriculture Foundation
AGCOagriFoundation@agcocorp.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom